StimLabs Enters Regenerative Medicine Market with Two Groundbreaking Amniotic Tissue Products

ROSWELL, Ga., July 25, 2017 /PRNewswire/ -- StimLabs is announcing two revolutionary products in regenerative medicine. Revita^®, the first full thickness placental membrane allograft in a shelf-stable format, and Ascent™, an amniotic fluid allograft that captures key amniotic fluid components in a shelf-stable powder. Processed using the patent-pending Clearify™ method, Revita preserves amnion, chorion and the intermediate layer of the membrane, making it the ideal barrier membrane in surgical applications and the optimal wound covering for chronic wounds. Processed using the patent-pending Selectify™ method, Ascent captures a consistent set of selected non-viable cells, proteins, and growth factors to protect, cushion, lubricate and reduce inflammation in fluid environments, such as joints and tendons. Both products have yielded positive early clinical feedback and are groundbreaking advancements in the $426 million amniotic tissue market.

The Revita Difference

• Revita is the first placental allograft to preserve all layers of the native placental membrane.
• By capturing the complete membrane, Revita maximizes the physical thickness required of a surgical barrier membrane and the growth factors desired for an optimal wound covering – all in a shelf-stable format.

The Ascent Difference

• While many amniotic fluid products advertise stem cell viability, independent research shows that there are few viable stem cells in amniotic fluid.¹ As the regenerative medicine field continues moving towards the power of cell signaling ², Ascent leverages the signaling components of non-viable cells, proteins, and growth factors to provide relief to targeted anatomies.
• The challenge of any regenerative medicine solution is delivering a consistent set of the appropriate elements. Using the Selectify process, Ascent extracts a consistent set of key non-viable cells, proteins and growth factors from native amniotic fluid and preserves them in a shelf-stable solution.

StimLabs was founded in 2015 with a focus on rapid, differentiated product iteration backed by robust scientific and clinical evidence. In pursuit of this goal, StimLabs' first two products leverage the unique capabilities of amniotic tissues. Amniotic tissues and fluids support the fetus throughout gestation and are rich in biological components that direct cellular activity. While these non-controversial tissues are typically discarded, StimLabs is using proprietary processing methods to capture and preserve these unique components in Revita and Ascent.

Future products in the StimLabs pipeline extend beyond placental-derived products to more advanced bioactive medical devices in regenerative medicine. Industry reports indicate that the global regenerative medicine market will expand from $18.9 billion in 2016 to over $53.7 billion by 2021. "Our approach is to rapidly develop and commercialize products that combine the unique benefits of pharmaceuticals, medical devices, and tissue transplants," said John Daniel, Founder and CEO of StimLabs. "To realize this goal, we've hired an exceptional team with over 100 years of experience across tissue engineering, cell biology, wound healing, and medical devices."

StimLabs is currently focusing on the following initiatives:

• Building a national independent distribution network of highly skilled, relationship-driven sales representatives
• Publishing robust scientific and clinical evidence to support product adoption
• Developing and commercializing next-generation technologies in regenerative medicine
• Managing increasing product demand through operational efficiencies and expansion

About StimLabs

StimLabs, LLC, was founded in 2015 with a desire to advance the state of regenerative medicine. Within a year of its inception, StimLabs built and certified an ISO Class 7 clean room facility, conceptualized and launched a suite of amniotic-derived products, developed an extensive product pipeline across a range of clinical applications, and established a portfolio of intellectual property. StimLabs portfolio of products includes Ascent™, a shelf-stable injectable amniotic fluid allograft, and Revita^®, an intact human placental membrane allograft that preserves all layers of the native tissue in a shelf-stable format. These groundbreaking products apply to a wide range of clinical applications and provide a foundation on which StimLabs is developing new regenerative technologies at the intersection of pharmaceuticals, medical devices, and tissue transplants. For more information, visit www.stimlabs.com.

Contact 
Chas Harris 
1225 Northmeadow Parkway                                           
Suite 104 
Roswell, GA  30076 
[email protected] 
www.stimlabs.com

1. Schiavo, A. Endothelial properties of third-trimester amniotic fluid stem cells cultured in hypoxia. Stem Cell Res Ther. 2015; 6: 209.

2. Caplan, A. Mesenchymal Stem Cells: Time to Change the Name! Stem Cells Transl Med. 2017 Jun;6(6):1445-1451.

SOURCE StimLabs